Systemic Therapy for Advanced or Metastatic Colorectal Cancer: National Comprehensive Cancer Network Guidelines for Combining Anti‐Vascular Endothelial Growth Factor and Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies with Chemotherapy
- 1 November 2008
- journal article
- practice guideline
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 28 (11P2) , 18S-20S
Abstract
During the past decade, new therapies for colorectal cancer have emerged that significantly prolong survival times. The introduction of these new agents has resulted in changes in colorectal cancer treatment patterns; clinicians are now able to optimize therapy and minimize toxicity by developing individualized patient treatment plans using a variety of agents. Biologic agents, including bevacizumab, an anti‐vascular endothelial growth factor (VEGF) monoclonal antibody, and cetuximab and panitumumab, anti‐epidermal growth factor receptor (EGFR) monoclonal antibodies, are among the new therapies now recommended by the National Comprehensive Cancer Network (NCCN) colon and rectal cancer treatment guidelines for use in first‐, second‐, and/or third‐line colorectal cancer therapy. According to the NCCN guidelines, patients with advanced or metastatic colorectal cancer who are without contraindications are candidates to receive the anti‐VEGF and anti‐EGFR monoclonal antibodies at some point during the treatment course.Keywords
This publication has 6 references indexed in Scilit:
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabAnnals of Oncology, 2007
- The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal CancerThe Oncologist, 2007
- A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinomaCancer, 1997